EPITHELIOID SARCOMA
Clinical trials for EPITHELIOID SARCOMA explained in plain language.
Never miss a new study
Get alerted when new EPITHELIOID SARCOMA trials appear
Sign up with your email to follow new studies for EPITHELIOID SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise for rare childhood tumors
Disease control OngoingThis phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression.…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New combo therapy targets rare childhood and adult cancers
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail targets childhood cancers with missing proteins
Disease control OngoingThis study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—in children with rare tumors that lack the INI1 or SMARCA4 proteins. The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific tumor types are being…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Susan Chi, MD • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cancer-Killing virus paired with immunotherapy shows promise in sarcoma trial
Disease control OngoingThis phase 2 study tests a combination of two drugs—talimogene laherparepvec (T-VEC), a virus that attacks cancer cells, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in 41 adults with advanced sarcoma that has spread or cannot be removed by surger…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC